On March 15th, Pfizer announced that its innovative tumor immunotherapy drug, Serenigme (Shuglizumab Injection), has been approved by the National Medical Products Administration for first-line treatment of locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma (G/GEJ) expressing PD-L1, in combination with fluorouracil and platinum containing drugs, Becoming the world's first PD-L1 monoclonal antibody approved for indication in gastric/gastroesophageal junction adenocarcinoma.